Report Code: A12326 | Pages: NA | Jul 2023 | 1301 Views | ||
Author(s) : Onkar S | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Growth Hormone Deficiency Market
Request Now !Human growth hormone (hGH) or somatotropin is a peptide hormone responsible for cell reproduction, growth stimulation, and cell regeneration in humans. In human growth hormone (GH) deficiency is caused when the pituitary gland is unable to synthesize enough concentration of hGH. This deficiency is treated by subcutaneously administering recombinant hGH. Various genetic disorders, including Turner syndrome and Prader–Willi syndrome, may cause growth hormone deficiency in humans, leading to shorter-than-average height and delayed puberty.
According to data published by the American Academy of Pediatrics, in the U.S., growth hormone deficiency affects less than one in 3,000 to one in 10,000 children. hGH is currently being abused by bodybuilders and athletes as an anti-aging treatment and as a performance-enhancing anabolic drug. However, according to the USFDA, hGH is a controlled substance that has not been authorized for anti-aging or performance-enhancing purposes.
COVID-19 Impact analysis
Following the COVID-19 outbreak, the emphasis has shifted toward the enhanced production of effective and affordable drugs, with the pandemic shining a light on healthcare inequities. For the accelerated drug development rate, the demand for real-world evidence has increased considerably, with major companies now opting for remote monitoring as well as source document verification (SDV), ensuring that patients can benefit despite the COVID-19 pandemic. While COVID-19 gets healthcare’s attention, growth hormone deficiency continues to be the focus areas in many countries. Therefore, studies are in progress to know the importance of growth hormone drugs and foster their application scope. In the post-pandemic era, the demand for the pediatric growth hormone market has also been favorable.
Top Impacting Factors
Market Trends
New product launches to flourish the market
In September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency.
In May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, indicated for pediatric growth hormone deficiency.
In November 2020, GenScience Pharmaceuticals entered an exclusive agreement with Foresee Pharmaceuticals for commercializing the latter’s FP-001 program, Leuprolide Mesylate Injectable Suspension—subcutaneous, ready-to-use 3-month and 6-month depot formulations or Camcevi. This agreement will be solely focusing on the Chinese market.
November 2020, Aeterna teamed up with Novo Nordisk with the aim to boost the application scope of macimorelin that helps diagnose growth hormone deficiency, which is childhood onset. The company believes that this area is considerably untapped, and therefore needs to explore the unmet needs. Aeterna is currently in the early stage of clinical safety as well as efficacy study, which focuses on analyzing Macimorelin for detection of CGHD.
Surge in GH Deficiency Cases to be a Key Growth Booster
Growth hormone deficiency has become a huge problem for the healthcare industry, and the most common reason for the same is considered to be a brain injury. This condition is marked with a host of symptoms, such as reduced energy levels, lower muscle strength, altered body composition, osteoporosis, insulin resistance, and lipid abnormalities that include high LDL cholesterol. Therefore, the growth hormone market share is expected to be bolstered by the rising GH deficiency disorders worldwide.
Key Benefits of the Report
Questions Answered in the Growth Hormone Deficiency Report
Growth Hormone Deficiency Market Report Highlights
Aspects | Details |
---|---|
By Brand |
|
By Application |
|
By End User |
|
By Region |
|
Key Market Players | Teva Pharmaceutical Industries, Ltd, Novartis AG, Merck KGaA, Novo Nordisk A/S, Ferring B.V., Roche, Ipsen, Eli Lilly and Company, Pfizer, Inc, Ferring Pharmaceuticals |
Loading Table Of Content...
Start reading.
This Report and over 53,854+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers